cd45 expression Search Results


ofpspark cd45 dna constructs  (Sino Biological)
90
Sino Biological ofpspark cd45 dna constructs
(A) A schematic representation of <t>anti-CD45/SLAMF6</t> (CD45/SLAMF6) binding to inhibit SLAMF6 clustering with CD3 in the IS. (B) αCD45/SLAMF6 antibody binding was quantified using an ELISA assay: αCD45 and αSLAMF6 binding was assessed against immobilized, recombinant ectodomains of CD45 and SLAMF6, respectively. (C) Jurkat T cells were transfected with GFP-tagged SLAMF6, and Raji B cells were stained with LifeAct Far Red and preloaded with SEE (2 ng/ml). Jurkat T cells were then co-cultured with Raji B cells for 30 min. Synapse formation with enrichment of SLAMF6 in the IS was visualized (top row). To visualize the distribution of CD45, we next transfected the Jurkat T cells with <t>OFPSpark-tagged</t> CD45 and GFP-tagged SLAMF6. In the Jurkat T–Raji B co-cultures, exclusion of CD45 was coupled with enrichment of SLAMF6 in the IS (middle row). Finally, we pretreated Jurkat T cells with anti-CD45/SLAMF6 10 µg/ml for 15 min (bottom image). Exclusion of CD45 was now associated with a lack of enrichment of SLAMF6 in the IS (bottom row). Images are representative of at least 40 cell conjugates per each experimental condition from two independent experiments. Scale bar is 5 μm. Percent of cell conjugates with SLAMF6 enrichment in the IS was quantified; results are summarized in the bar graph. (D) Jurkat T cells were treated with αCD3 and αCD45/SLAMF6 at three different concentrations: 0.1, 1, and 10 µg/ml of the bispecific antibody. After 24 h, IL-2 levels were analyzed by ELISA. (E) Raji B cells were preloaded with different concentrations of SEE and co-cultured with Jurkat T cells in the absence (blue) or presence (magenta) of 1 µg/ml of αCD45/SLAMF6 antibody. IL-2 levels were analyzed for at least three independent experiments (n = 3). (F) Raji B cells were preloaded with SEE and co-cultured with T cells at increasing concentrations of αCD45/SLAMF6 antibody. IL-2 levels were analyzed for at least three independent experiments (n = 3). (G) Raji B cells and Jurkat T cells were co-cultured either in the presence of, or after T cell pretreatment with, αCD45/SLAMF6. Specifically, in the first experimental condition, αCD45/SLAMF6 was added as Jurkat T–Raji B conjugates formed (supporting in trans antibody ligation), whereas in the second experimental condition, Jurkat T cells were pretreated with αCD4/SLAMF6 for 30 min, washed, and subsequently co-cultured with the Raji B cells, supporting in cis antibody ligation on T cells before addition of the B cells. IL-2 levels were analyzed for at least three independent experiments (n = 3). * P < 0.05 for an unpaired t test.
Ofpspark Cd45 Dna Constructs, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd45+expression/pmc09733572-216-0-6?v=Sino+Biological
Average 90 stars, based on 1 article reviews
ofpspark cd45 dna constructs - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
human cd45 ptprc transcript variant 1 gene lentiviral orf cdna expression plasmid c gfpspark tag  (Sino Biological)
N/A
Full length Clone DNA of Homo sapiens protein tyrosine phosphatase receptor type C transcript variant 1
   Buy from Supplier
human cd45 ptprc transcript variant 1 gene orf cdna clone expression plasmid n myc tag  (Sino Biological)
N/A
Full length Clone DNA of Human protein tyrosine phosphatase receptor type C transcript variant 1 with N terminal Myc tag
   Buy from Supplier
human cd45 ptprc transcript variant 2 gene orf cdna clone expression plasmid c gfpspark tag  (Sino Biological)
N/A
Full length Clone DNA of Human protein tyrosine phosphatase receptor type C transcript variant 2 with C terminal GFPSpark tag
   Buy from Supplier
human cd45 ptprc transcript variant 2 gene orf cdna clone expression plasmid  (Sino Biological)
N/A
Full length Clone DNA of Human protein tyrosine phosphatase receptor type C transcript variant 2
   Buy from Supplier
human cd45 ptprc transcript variant 1 gene orf cdna clone expression plasmid c gfpspark tag  (Sino Biological)
N/A
Full length Clone DNA of Human protein tyrosine phosphatase receptor type C transcript variant 1 with C terminal GFPSpark tag
   Buy from Supplier
human cd45 ptprc transcript variant 2 gene orf cdna clone expression plasmid c his tag  (Sino Biological)
N/A
Full length Clone DNA of Human protein tyrosine phosphatase receptor type C transcript variant 2 with C terminal His tag
   Buy from Supplier
human cd45 ptprc transcript variant 1 gene orf cdna clone expression plasmid c flag tag  (Sino Biological)
N/A
Full length Clone DNA of Human protein tyrosine phosphatase receptor type C transcript variant 1 with C terminal Flag tag
   Buy from Supplier
mouse cd45 ptprc gene orf cdna clone expression plasmid  (Sino Biological)
N/A
Full length Clone DNA of Mouse protein tyrosine phosphatase receptor type C
   Buy from Supplier
human cd45 ptprc transcript variant 1 gene orf cdna clone expression plasmid n his tag  (Sino Biological)
N/A
Full length Clone DNA of Human protein tyrosine phosphatase receptor type C transcript variant 1 with N terminal His tag
   Buy from Supplier
human cd45 ptprc transcript variant 2 gene orf cdna clone expression plasmid c flag tag  (Sino Biological)
N/A
Full length Clone DNA of Human protein tyrosine phosphatase receptor type C transcript variant 2 with C terminal Flag tag
   Buy from Supplier
human cd45 ptprc transcript variant 1 gene orf cdna clone expression plasmid c his tag  (Sino Biological)
N/A
Full length Clone DNA of Human protein tyrosine phosphatase receptor type C transcript variant 1 with C terminal His tag
   Buy from Supplier

Image Search Results


(A) A schematic representation of anti-CD45/SLAMF6 (CD45/SLAMF6) binding to inhibit SLAMF6 clustering with CD3 in the IS. (B) αCD45/SLAMF6 antibody binding was quantified using an ELISA assay: αCD45 and αSLAMF6 binding was assessed against immobilized, recombinant ectodomains of CD45 and SLAMF6, respectively. (C) Jurkat T cells were transfected with GFP-tagged SLAMF6, and Raji B cells were stained with LifeAct Far Red and preloaded with SEE (2 ng/ml). Jurkat T cells were then co-cultured with Raji B cells for 30 min. Synapse formation with enrichment of SLAMF6 in the IS was visualized (top row). To visualize the distribution of CD45, we next transfected the Jurkat T cells with OFPSpark-tagged CD45 and GFP-tagged SLAMF6. In the Jurkat T–Raji B co-cultures, exclusion of CD45 was coupled with enrichment of SLAMF6 in the IS (middle row). Finally, we pretreated Jurkat T cells with anti-CD45/SLAMF6 10 µg/ml for 15 min (bottom image). Exclusion of CD45 was now associated with a lack of enrichment of SLAMF6 in the IS (bottom row). Images are representative of at least 40 cell conjugates per each experimental condition from two independent experiments. Scale bar is 5 μm. Percent of cell conjugates with SLAMF6 enrichment in the IS was quantified; results are summarized in the bar graph. (D) Jurkat T cells were treated with αCD3 and αCD45/SLAMF6 at three different concentrations: 0.1, 1, and 10 µg/ml of the bispecific antibody. After 24 h, IL-2 levels were analyzed by ELISA. (E) Raji B cells were preloaded with different concentrations of SEE and co-cultured with Jurkat T cells in the absence (blue) or presence (magenta) of 1 µg/ml of αCD45/SLAMF6 antibody. IL-2 levels were analyzed for at least three independent experiments (n = 3). (F) Raji B cells were preloaded with SEE and co-cultured with T cells at increasing concentrations of αCD45/SLAMF6 antibody. IL-2 levels were analyzed for at least three independent experiments (n = 3). (G) Raji B cells and Jurkat T cells were co-cultured either in the presence of, or after T cell pretreatment with, αCD45/SLAMF6. Specifically, in the first experimental condition, αCD45/SLAMF6 was added as Jurkat T–Raji B conjugates formed (supporting in trans antibody ligation), whereas in the second experimental condition, Jurkat T cells were pretreated with αCD4/SLAMF6 for 30 min, washed, and subsequently co-cultured with the Raji B cells, supporting in cis antibody ligation on T cells before addition of the B cells. IL-2 levels were analyzed for at least three independent experiments (n = 3). * P < 0.05 for an unpaired t test.

Journal: Life Science Alliance

Article Title: SLAMF6 compartmentalization enhances T cell functions

doi: 10.26508/lsa.202201533

Figure Lengend Snippet: (A) A schematic representation of anti-CD45/SLAMF6 (CD45/SLAMF6) binding to inhibit SLAMF6 clustering with CD3 in the IS. (B) αCD45/SLAMF6 antibody binding was quantified using an ELISA assay: αCD45 and αSLAMF6 binding was assessed against immobilized, recombinant ectodomains of CD45 and SLAMF6, respectively. (C) Jurkat T cells were transfected with GFP-tagged SLAMF6, and Raji B cells were stained with LifeAct Far Red and preloaded with SEE (2 ng/ml). Jurkat T cells were then co-cultured with Raji B cells for 30 min. Synapse formation with enrichment of SLAMF6 in the IS was visualized (top row). To visualize the distribution of CD45, we next transfected the Jurkat T cells with OFPSpark-tagged CD45 and GFP-tagged SLAMF6. In the Jurkat T–Raji B co-cultures, exclusion of CD45 was coupled with enrichment of SLAMF6 in the IS (middle row). Finally, we pretreated Jurkat T cells with anti-CD45/SLAMF6 10 µg/ml for 15 min (bottom image). Exclusion of CD45 was now associated with a lack of enrichment of SLAMF6 in the IS (bottom row). Images are representative of at least 40 cell conjugates per each experimental condition from two independent experiments. Scale bar is 5 μm. Percent of cell conjugates with SLAMF6 enrichment in the IS was quantified; results are summarized in the bar graph. (D) Jurkat T cells were treated with αCD3 and αCD45/SLAMF6 at three different concentrations: 0.1, 1, and 10 µg/ml of the bispecific antibody. After 24 h, IL-2 levels were analyzed by ELISA. (E) Raji B cells were preloaded with different concentrations of SEE and co-cultured with Jurkat T cells in the absence (blue) or presence (magenta) of 1 µg/ml of αCD45/SLAMF6 antibody. IL-2 levels were analyzed for at least three independent experiments (n = 3). (F) Raji B cells were preloaded with SEE and co-cultured with T cells at increasing concentrations of αCD45/SLAMF6 antibody. IL-2 levels were analyzed for at least three independent experiments (n = 3). (G) Raji B cells and Jurkat T cells were co-cultured either in the presence of, or after T cell pretreatment with, αCD45/SLAMF6. Specifically, in the first experimental condition, αCD45/SLAMF6 was added as Jurkat T–Raji B conjugates formed (supporting in trans antibody ligation), whereas in the second experimental condition, Jurkat T cells were pretreated with αCD4/SLAMF6 for 30 min, washed, and subsequently co-cultured with the Raji B cells, supporting in cis antibody ligation on T cells before addition of the B cells. IL-2 levels were analyzed for at least three independent experiments (n = 3). * P < 0.05 for an unpaired t test.

Article Snippet: OFPSpark-CD45 DNA constructs were obtained from Sino Biologics (#HG10086-ACR).

Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Recombinant, Transfection, Staining, Cell Culture, Ligation

Bispecific antibodies, anti-CD3/SLAMF6 and anti-CD45/SLAMF6, were supplemented with 1 M HEPS buffer, and purity was determined by running PAGE gel against 1 µg of BSA as a control.

Journal: Life Science Alliance

Article Title: SLAMF6 compartmentalization enhances T cell functions

doi: 10.26508/lsa.202201533

Figure Lengend Snippet: Bispecific antibodies, anti-CD3/SLAMF6 and anti-CD45/SLAMF6, were supplemented with 1 M HEPS buffer, and purity was determined by running PAGE gel against 1 µg of BSA as a control.

Article Snippet: OFPSpark-CD45 DNA constructs were obtained from Sino Biologics (#HG10086-ACR).

Techniques:

PBMCs were treated with SEE and three different concentrations of either the monovalent (αCD45/SLAMF6) or the bivalent (αCD45-Ig-SLAMF6) anti-CD45/SLAMF6–bispecific antibody. (A, B) After 24 h, (A) IL-2 and (B) IFN-γ levels were measured by ELISA. The results of at least three independent experiments (n = 3) are shown. (C, D) Primary human CD3-positive T cells were isolated from whole blood and cultured with anti-CD3 in the presence αCD45/SLAMF6. (C) After 5 min, the cells were analyzed for phosphorylation of CD3 ζ chain using flow cytometry. (D) After 24 h, the cells were analyzed for CD69 expression, and the supernatant was analyzed for IL-2 and IFN-y release. * P < 0.05, ** P < 0.01 for an unpaired t test.

Journal: Life Science Alliance

Article Title: SLAMF6 compartmentalization enhances T cell functions

doi: 10.26508/lsa.202201533

Figure Lengend Snippet: PBMCs were treated with SEE and three different concentrations of either the monovalent (αCD45/SLAMF6) or the bivalent (αCD45-Ig-SLAMF6) anti-CD45/SLAMF6–bispecific antibody. (A, B) After 24 h, (A) IL-2 and (B) IFN-γ levels were measured by ELISA. The results of at least three independent experiments (n = 3) are shown. (C, D) Primary human CD3-positive T cells were isolated from whole blood and cultured with anti-CD3 in the presence αCD45/SLAMF6. (C) After 5 min, the cells were analyzed for phosphorylation of CD3 ζ chain using flow cytometry. (D) After 24 h, the cells were analyzed for CD69 expression, and the supernatant was analyzed for IL-2 and IFN-y release. * P < 0.05, ** P < 0.01 for an unpaired t test.

Article Snippet: OFPSpark-CD45 DNA constructs were obtained from Sino Biologics (#HG10086-ACR).

Techniques: Enzyme-linked Immunosorbent Assay, Isolation, Cell Culture, Flow Cytometry, Expressing